Intralesional steroid injection for the management of otohematoma
DC Field | Value | Language |
---|---|---|
dc.contributor.author | Im, Gi Jung | - |
dc.contributor.author | Chae, Sung Won | - |
dc.contributor.author | Choi, Jun | - |
dc.contributor.author | Kim, Yang Soo | - |
dc.contributor.author | Kim, Woo Joo | - |
dc.contributor.author | Jung, Hak Hyun | - |
dc.date.accessioned | 2021-09-09T06:59:58Z | - |
dc.date.available | 2021-09-09T06:59:58Z | - |
dc.date.created | 2021-06-10 | - |
dc.date.issued | 2008-07 | - |
dc.identifier.issn | 0194-5998 | - |
dc.identifier.uri | https://scholar.korea.ac.kr/handle/2021.sw.korea/123282 | - |
dc.description.abstract | OBJECTIVES: To compare the therapeutic efficacies of aspiration plus intralesional steroid injection and aspiration plus pressure dressing for the management of otohematoma. STUDY DESIGN AND SETTING: Fifteen patients with otohematoma were treated by aspiration plus pressure dressing (the pressure dressing group) and 34 patients were treated with intralesional steroid injections followed by simple aspiration (the steroid injection group). RESULTS: Otohematoma resolved within four weeks in all 15 patients in the pressure dressing group, but eight of the 15 showed perichondrial thickening. The duration of treatment was shorter in the steroid injection group than in the pressure dressing group; 14 (41.2%) of the 34 recovered after the first injections and another 15 (44.1%) after the second, and the remaining 5 (14.7%) after the third without any complications. However, multiple steroid injections are needed due to a high early recurrence rate. CONCLUSION: intralesional steroid injection is the treatment of choice for the management of otohematoma. The correction of causative use of a hard pillow, a helmet, and headphones is essential to prevent late recurrence. (C) 2008 American Academy of Otolaryngology-Head and Neck Surgery Foundation. All rights reserved. | - |
dc.language | English | - |
dc.language.iso | en | - |
dc.publisher | SAGE PUBLICATIONS LTD | - |
dc.subject | THERAPY | - |
dc.subject | PSEUDOCYST | - |
dc.subject | EAR | - |
dc.subject | HEMATOMA | - |
dc.subject | AURICLE | - |
dc.title | Intralesional steroid injection for the management of otohematoma | - |
dc.type | Article | - |
dc.contributor.affiliatedAuthor | Im, Gi Jung | - |
dc.contributor.affiliatedAuthor | Chae, Sung Won | - |
dc.contributor.affiliatedAuthor | Choi, Jun | - |
dc.contributor.affiliatedAuthor | Jung, Hak Hyun | - |
dc.identifier.doi | 10.1016/j.otohns.2008.01.006 | - |
dc.identifier.scopusid | 2-s2.0-45549100665 | - |
dc.identifier.wosid | 000257530300020 | - |
dc.identifier.bibliographicCitation | OTOLARYNGOLOGY-HEAD AND NECK SURGERY, v.139, no.1, pp.115 - 119 | - |
dc.relation.isPartOf | OTOLARYNGOLOGY-HEAD AND NECK SURGERY | - |
dc.citation.title | OTOLARYNGOLOGY-HEAD AND NECK SURGERY | - |
dc.citation.volume | 139 | - |
dc.citation.number | 1 | - |
dc.citation.startPage | 115 | - |
dc.citation.endPage | 119 | - |
dc.type.rims | ART | - |
dc.type.docType | Article | - |
dc.description.journalClass | 1 | - |
dc.description.journalRegisteredClass | scie | - |
dc.description.journalRegisteredClass | scopus | - |
dc.relation.journalResearchArea | Otorhinolaryngology | - |
dc.relation.journalResearchArea | Surgery | - |
dc.relation.journalWebOfScienceCategory | Otorhinolaryngology | - |
dc.relation.journalWebOfScienceCategory | Surgery | - |
dc.subject.keywordPlus | THERAPY | - |
dc.subject.keywordPlus | PSEUDOCYST | - |
dc.subject.keywordPlus | EAR | - |
dc.subject.keywordPlus | HEMATOMA | - |
dc.subject.keywordPlus | AURICLE | - |
dc.subject.keywordAuthor | Otohematoma | - |
Items in ScholarWorks are protected by copyright, with all rights reserved, unless otherwise indicated.
(02841) 서울특별시 성북구 안암로 14502-3290-1114
COPYRIGHT © 2021 Korea University. All Rights Reserved.
Certain data included herein are derived from the © Web of Science of Clarivate Analytics. All rights reserved.
You may not copy or re-distribute this material in whole or in part without the prior written consent of Clarivate Analytics.